Literature DB >> 100121

Chrysotherapy. Suppression of immunoglobulin synthesis.

A Lorber, T Simon, J Leeb, A Peter, S Wilcox.   

Abstract

Forty-four subjects with classic or definite rheumatoid arthritis who were on individualized chrysotherapy were observed for changes in serum protein electrophoresis, immunoglobulins, and circulating lymphocyte counts. By paired variate analysis, significant declines from pretreatment values were recorded for the following--electrophoretic protein fractions: gamma, alpha-1, alpha-2, (P less than 0.05); immunoglobulins: IgM--53% (P less than 0.001), IgG--37% (P less than 0.01), IgA--34% (P less than 0.001). Rheumatoid factor decreased in 29 of 39 subjects, 15 becoming seronegative (P less than 0.001); circulating lymphocytes decreased by 27% (P less than 0.001). The maximal suppressive effect on IgG and IgM was not achieved until the third and fourth years of therapy by sustained weekly administration of gold sodium thiomalate (one year cumulative dosage, mean 2106 mg, range 1065-2,885; greater than or equal to 4 year cumulative dosage, mean 8747 mg, range 5,385-15,160 mg). An immunosuppressive effect is suggested by these results.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100121     DOI: 10.1002/art.1780210708

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  Serum immunoglobulins and the risk of rheumatoid arthritis.

Authors:  K Aho; M Heliövaara; P Knekt; A Reunanen; A Aromaa; A Leino; P Kurki; R Heikkilä; T Palosuo
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

2.  The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis.

Authors:  J Hassan; J Hanly; B Bresnihan; C Feighery; C A Whelan
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

3.  Antibody deficiency associated with gold treatment: natural history and management in 22 patients.

Authors:  N Snowden; D M Dietch; L S Teh; R C Hilton; M R Haeney
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

4.  Effect of drug therapy on circulating and synovial fluid Ig-secreting cells in rheumatoid arthritis.

Authors:  S Al-Balaghi; H Ström; E Möller
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

5.  Hypogammaglobulinaemia associated with gold therapy.

Authors:  A K So; S A Peskett; A D Webster
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

Review 6.  Mechanisms of action of gold.

Authors:  J H Leibfarth; R H Persellin
Journal:  Agents Actions       Date:  1981-11

Review 7.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

8.  Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.

Authors:  K Hashimoto; C E Whitehurst; T Matsubara; K Hirohata; P E Lipsky
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  One year treatment with low dose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors.

Authors:  A Spadaro; V Riccieri; A Sili Scavalli; E Taccari; A Zoppini
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

Review 10.  The genetics of hypogammaglobulinemia.

Authors:  Bodo Grimbacher; Alejandro A Schäffer; Hans-Hartmut Peter
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.